Accessibility Menu
TELA Bio logo

TELA Bio(NASDAQ) TELA

Market Cap$32.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-95%
5 Year-95%
1 Year-60%
1 Month+3%
$0.74
+1.38%
+0.01Today
After hours$0.74+$0.00 (+0.00%)
TELA Bio last closing stock price
MetricPriceDate
Last closeUSD 0.742026-08-03
TELA Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.85%USD 0.652026-07-27
1 month+2.58%USD 0.722026-07-02
3 month-34.51%USD 1.132026-05-05
Year to date-37.29%USD 1.182025-12-31
1 year-60.22%USD 1.862025-08-01
3 year-92.37%USD 9.702023-08-04
5 year-94.63%USD 13.792021-08-04
Since inception-94.53%USD 13.352019-11-08

TELA Bio Financials at a Glance

Market Cap

$32.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$80.81M

Net Income (TTM)

-$39.84M

EPS (TTM)

-$0.80

P/E Ratio

-0.92

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$0.74

Volume

99,530

Open

$0.73

Previous Close

$0.74

Daily Range

$0.72 - $0.76

52-Week Range

$0.50 - $2.14

Estimated Earnings Date

Aug 10, 2026

TELA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TELA Bio

TelA Bio makes medical products that help repair soft tissue, like hernias. Its main products support surgeons in fixing abdominal injuries and reconstructive surgeries. These solutions aim to help patients heal better and faster after surgery.

Products and Services

  • OviTex Reinforced Tissue Matrix: For hernia repair and abdominal wall reconstruction; 64% of 2025 revenue.
  • OviTex PRS Reinforced Tissue Matrix: For plastic and reconstructive surgery.
  • OviTex LPR and IHR: For minimally invasive hernia repairs, including robotic and laparoscopic procedures.
  • LIQUIFIX Mesh Fixation Devices: Used to secure hernia mesh during surgery; distributed in the U.S.
  • Other Products: Includes legacy and discontinued items.

Growth and Expansion

  • Launched larger OviTex LPR products for complex hernias in 2023.
  • Introduced OviTex IHR for inguinal hernia repair in the U.S. (2024) and Europe (2025).
  • Released OviTex PRS Long-Term Resorbable in 2023 and larger PRS sizes in 2025.
  • Signed U.S. distribution deal for LIQUIFIX with Advanced Medical Solutions in 2023.
  • Sold NIVIS product rights to MiMedx Group in 2024 for upfront and future payments.

What Makes TELA Bio Stand Out

TelA Bio combines natural and synthetic materials to create surgical implants that balance strength and healing. Its exclusive supply chain and broad patent portfolio support its competitive position. The company focuses on direct sales in the U.S. and select international markets, using group purchasing contracts to reach hospitals.

Five Things You Need to Know

  • Revenue was $80.3 million in 2025, up 16% from 2024.
  • Gross margin was 68% in 2025, up from 67% in 2024.
  • Net loss was $(38.8) million in 2025, slightly higher than 2024.
  • International sales were $12.1 million in 2025, 15% of total revenue.
  • OviTex unit sales grew 22% in 2025; OviTex PRS units grew 12%.

Bottom Line

TelA Bio has expanded its product range and global reach while focusing on soft-tissue repair. The company continues to adapt through innovation and strategic partnerships.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

218

CEO

Antony Koblish

Website

www.telabio.com

Headquarters

Malvern, PA 19355, US

TELA Financials

Key Financial Metrics (TTM)

Gross Margin

67.25%

Operating Margin

-41.84%

Net Income Margin

-49.30%

Return on Equity

-1344.47%

Return on Capital

-54.47%

Return on Assets

-57.00%

Earnings Yield

-1.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

44.77M

Volume

99.53K

Avg. Volume

128.21K

Financials (TTM)

Gross Profit

$54.35M

Operating Income

-$33.81M

EBITDA

-$32.52M

Operating Cash Flow

-$29.66M

Capital Expenditure

-$535.00K

Free Cash Flow

-$30.20M

Cash & ST Invst.

$39.54M

Total Debt

$56.39M

TELA Bio Performance Analysis

TELA Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 41,418,00040.6%
20232023-12-31USD 58,453,00041.1%
20242024-12-31USD 69,300,00018.6%
20252025-12-31USD 80,275,00015.8%
TELA Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-309.1%
Q32025-09-302.4%
Q42025-12-310.9%
Q12026-03-31-8.7%
TELA Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7218.4%
20232023-12-31USD -2.04-25.1%
20242024-12-31USD -1.33-35.0%
20252025-12-31USD -0.83-37.6%
TELA Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.0%
Q32025-09-3013.6%
Q42025-12-3110.5%
Q12026-03-31-23.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$19.06M

+2.9%

Gross Profit

$12.52M

+0.1%

Gross Margin

65.69%

N/A

Market Cap

$32.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$149.88K

N/A

Employees

218

N/A

Net Income

-$12.27M

-9.0%

EBITDA

-$9.90M

-1.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$39.54M

-7.7%

Total Debt

$56.39M

+34.9%

Accounts Receivable

$9.72M

-16.7%

Inventory

$12.21M

-9.8%

Long Term Debt

$55.87M

+35.4%

Short Term Debt

$527.00K

-0.9%

Return on Assets

-57.00%

N/A

Return on Invested Capital

-64.94%

N/A

Free Cash Flow

-$11.29M

-15.7%

Operating Cash Flow

-$11.17M

-14.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTLKOutlook Therapeutics, Inc.
$0.91-6.51%
COEPCoeptis Therapeutics Holdings, Inc.
$10.99-8.57%
CTSOCytosorbents Corporation
$0.37+2.00%
SRTSSensus Healthcare, Inc.
$2.92+0.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About TELA

What is the current price of TELA Bio?

TELA Bio is trading at $0.74 per share.

What is the 52-week range for TELA Bio?

Over the past 52 weeks, TELA Bio has traded between $0.50 and $2.14.

How much debt does TELA Bio have?

As of the most recent reporting period, TELA Bio reported total debt of $56.39M.

How much cash does TELA Bio have on hand?

TELA Bio reported $39.54M in cash and cash equivalents in its most recent financial results.

What is TELA Bio’s dividend yield?

TELA Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services